Unraveling covid-19: a global health crisis and ongoing research | [Futuristic Biotechnology • 2023]

Author(s):

1. Osama Alam: Department of Biotechnology, University of Science & Technology, Bannu, Pakistan

2. Muhammad Ahmad: Department of Zoology, Quaid-E- Azam University, Islamabad, Pakistan

3. Munib Qureshi: Department of Biotechnology, University of Science & Technology, Bannu, Pakistan

4. Marina Gul: Department of Botany, University of Science & Technology, Bannu, Pakistan

5. Naveed Khan: Department of Zoology, Govt. Post Graduate College, Bannu, Pakistan

6. Abdul Samad: Department of Biotechnology and Genetic Engineering, Kohat University of Science and Technology, Kohat, Pakistan

7. Zewran Khan: Department of Biotechnology, University of Science & Technology, Bannu, Pakistan

8. Syed Atiq: Department of Chemistry, University of Science & Technology, Bannu, Pakistan

9. Arsalan Iqbal: Department of Biotechnology, University of Science & Technology, Bannu, Pakistan

10. Asim Ullah: Department of Zoology, Govt. Post Graduate College, Bannu, Pakistan

Abstract:

The COVID-19 pandemic, sparked by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered an unparalleled global health crisis with far-reaching consequences. SARS-CoV-2 primarily spreads through respiratory droplets, utilizing angiotensin-converting enzyme 2 (ACE2) receptors in the respiratory system for cellular entry and replication, underscoring the critical need for preventive measures. The emergence of worrisome mutations has led to the development of more transmissible variants, heightening the virus's potential impact. Diagnostic testing, including reverse-transcriptase polymerase chain reaction (RT-PCR), antigen detection, and serology, plays a pivotal role in identifying. COVID-19 diagnostic tests include the ABBOTT ID NOW™ COVID-19 test (95% sensitivity and 100% specificity), the COBAS® SARS-CoV-2 test (98.8% sensitivity and 99% specificity), the SOFIA® 2 SARS ANTIGEN FIA test (91.7% sensitivity and 100% specificity), the XPERT® XPRESS SARS-CoV-2 test (95.4% sensitivity and 97% specificity), and the ACCULA SARS-CoV-2 test (98% sensitivity and 100% specificity). While vaccines include the Pfizer-BioNTech vaccine (95% efficacy), Moderna vaccine (94.10% efficacy), Johnson & Johnson vaccine (66% efficacy), Oxford-AstraZeneca vaccine (76% efficacy), Sinovac vaccine (50.38% efficacy), Sinopharm vaccine (79% efficacy), Bharat Biotech (Covaxin) vaccine (81% efficacy), Sputnik V vaccine (91.60% efficacy), Novavax vaccine (96.4% efficacy), and Covovax vaccine (100% efficacy). The COVID-19 pandemic underscores the ongoing necessity for global cooperation among scienti??c and medical communities to understand this emerging pathogen, mitigate health impacts, and advance long-term solutions through continuous therapeutic and vaccine research.

Page(s): 10-18

DOI: 10.54393/fbt.v3i02.47

Published: Journal: Futuristic Biotechnology, Volume: 3, Issue: 2, Year: 2023

Keywords:

COVID19 , COVID19 , SARSCoV2 , angiotensinconverting enzyme 2

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views